Akero Therapeutics Inc

Akero Therapeutics, Inc. operates as a cardio-metabolic nonalcoholic steatohepatitis company, which engages in developing pioneering medicines designed to restore metabolic balance and improve overall health. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph on January 24, 2017 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.

Here is how Akero Therapeutics, Inc. (AKRO) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

Are Medical Stocks Lagging Akero Therapeutics (AKRO) This Year?

Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category

Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD's The Liver Meeting® 2022

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today reported third quarter financial results for the period ending September 30, 2022 and provided business updates.

Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

Astria Therapeutics

HeartBeam

ContraFect

Humanigen

Otonomy

Rhythm Pharmaceuticals

Vigil Neuroscience

Virios Therapeutics

The healthcare industry is now starting to shift its focus away from the coronavirus pandemic to work on its core activities.

These Were the Five Best and Worst Performing Healthcare Stocks in Q3 2022

Acumen Pharmaceuticals

FaZe Holdings Inc

Forge Global Holdings Inc

Grove Collaborative Holdings

Immuneering Corp

Novavax

Cassava Sciences Inc

Value Line

Ventyx Biosciences

Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.

These Are the Five Best and Worst Performing Small-cap Stocks in September 2022

Applied DNA Sciences

Avenue Therapeutics

Mind Medicine MindMed

PhaseBio Pharmaceuticals Inc

Shuttle Pharmaceuticals Holdings Inc

Spero Therapeutics

September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%.

These Were The Five Best And Worst Performing Healthcare Stocks In September 2022

88% technical buy signals. 7 new highs and up 222.89% in the last month.

Akero Therapeutics - Biotechnology

SOUTH SAN FRANCISCO, Calif., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the H.C. Wainwright 6th Annual NASH Virtual Investor Conference on Monday, October 17, 2022, at 12:00 p.m. E.T.

Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference

Amgen

Biogen

bluebird bio

Chemocentryx

Forma Therapeutics Holdings

iShares Nasdaq Biotechnology ETF

Karuna Therapeutics Inc

Novo Nordisk

Pfizer

SPDR S&P Biotech ETF

Biotechs are relatively better positioned in this fourth quarter compared to the broader market. Path of interest rates is clearer for 2022 and the Fed is closer to a pause early next year as it calibrates down its response from a hammer approach.

Biotech Stocks Well-Positioned For Fourth Quarter

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the closing of its previously announced upsized underwritten public offering of 8,846,154 shares of its common stock at a public offering price of $26.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,153,846 shares of common stock in this offering. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $230.0 million.

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Aerie Pharmaceuticals

Belite Bio Inc

Catalyst Pharmaceuticals

Verona Pharma

Gossamer Bio Inc

Relmada Therapeutics Inc

Viridian Therapeutics

The double-digit run for biotech stocks off a June bottom is great — until you realize you could've netted more by investing in the best. The post Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year appeared first on Investor's Business Daily.

Here Are 10 Biotech Stocks — Including Catalyst And Viridian — That Would Have Netted You $10,000 More This Year

Despite the recent resurgence, many biotech innovators are still trading at a fraction of their intrinsic value. In studying the biotech landscape, I recently uncovered another promising innovator dubbed Akero Therapeutics.

Akero Therapeutics: A Promising NASH Innovator

Akero Therapeutics recently posted solid phase 2b data. Akero appears adequately funded.

Akero Therapeutics: Outstanding Data In NASH

SOUTH SAN FRANCISCO, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an upsized underwritten public offering of 7,692,308 shares of its common stock at a public offering price of $26.00 per share. All of the shares in the offering are being offered by Akero Therapeutics. In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,153,846 shares of its common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $200.0 million, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about September 19, 2022, subject to the satisfaction of customary closing conditions.

Akero Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

Akero Therapeutics (AKRO) reports positive top-line data from a mid-stage study evaluating its lead candidate, efruxifermin (EFX), in patients with NASH, fibrosis stage 2 or 3 (F2-F3). Stock up.

Akero Therapeutics (AKRO) Up on Positive Data from NASH Study

Akero Therapeutics reported positive mid-stage NASH trial results. Akero immediately announced a stock offering to raise cash.

Akero Therapeutics' Positive NASH Trial Results And Cash Raise

The biotech's experimental NASH drug hit the mark in a key phase 2b trial.

Why Akero Therapeutics Stock Is on Fire Today

Akero Therapeutics (NASDAQ: AKRO ) stock is soaring 120% and is one of today's top trending tickers on sites like Yahoo Finance. The rally was sparked by the company's release of positive data on its drug candidate, efruxifermin, or EFX.

Why Is Akero Therapeutics (AKRO) Stock Up 120% Today?

Akero wowed investors Tuesday with midstage test results for a hepatitis treatment, and the biotech stock skyrocketed by triple digits. The post Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment appeared first on Investor's Business Daily.

Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment

Peloton

As the connected fitness equipment maker keeps going through turmoil, good news helped lift a largely unknown company's share price.

Peloton's Shake-Up Continues, but This Tiny Stock Doubled Early Tuesday

Shares of Akero Therapeutics Inc. AKRO, +4.78% soared 101.1% in premarket trading on Tuesday after the company said its experimental treatment for nonalcoholic steatohepatitis met a primary and secondary endpoint in a Phase 2b clinical trial. NASH is a liver disease.

Akero's experimental NASH drug meets the primary endpoint in a clinical trial

50mg (41%) and 28mg (39%) groups demonstrated ≥1 stage improvement in fibrosis without worsening of NASH, double the placebo rate (20%)

In Akero Therapeutics' Phase 2b HARMONY Study, Both the 50mg and 28mg EFX Doses Achieved Statistical Significance on Primary and Secondary Histology Endpoints after 24 Weeks

Investor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical data Investor webcast on Tuesday, September 13 at 8:00 a.m. ET to present clinical data

Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH

Akero Therapeutics (AKRO) announces positive data from third cohort of its mid-stage study evaluating efruxifermin (EFX) in NASH. Stock up.

Akero Therapeutics (AKRO) Up on Positive NASH Study Data

33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution

Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment

News for Akero Therapeutics Inc Stock (AKRO)